481 related articles for article (PubMed ID: 10372650)
1. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of phosphodiesterase inhibitors on accumulation of cyclic AMP in isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
Biochem Pharmacol; 1995 Feb; 49(4):441-52. PubMed ID: 7872950
[TBL] [Abstract][Full Text] [Related]
4. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
Br J Pharmacol; 1993 Dec; 110(4):1387-94. PubMed ID: 8306078
[TBL] [Abstract][Full Text] [Related]
5. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid.
Matousovic K; Tsuboi Y; Walker H; Grande JP; Dousa TP
J Lab Clin Med; 1997 Nov; 130(5):487-95. PubMed ID: 9390636
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.
Pan X; Arauz E; Krzanowski JJ; Fitzpatrick DF; Polson JB
Biochem Pharmacol; 1994 Aug; 48(4):827-35. PubMed ID: 7521642
[TBL] [Abstract][Full Text] [Related]
8. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
9. Control of cyclic AMP levels in primary cultures of human tracheal smooth muscle cells.
Hall IP; Widdop S; Townsend P; Daykin K
Br J Pharmacol; 1992 Oct; 107(2):422-8. PubMed ID: 1384913
[TBL] [Abstract][Full Text] [Related]
10. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
11. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: effects on airways smooth muscle.
Raeburn D; Advenier C
Int J Biochem Cell Biol; 1995 Jan; 27(1):29-37. PubMed ID: 7757880
[TBL] [Abstract][Full Text] [Related]
12. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
13. Resensitization of hepatocyte glucagon-stimulated adenylate cyclase can be inhibited when cyclic AMP phosphodiesterase inhibitors are used to elevate intracellular cyclic AMP concentrations to supraphysiological values.
Murphy GJ; Houslay MD
Biochem J; 1988 Jan; 249(2):543-7. PubMed ID: 2449179
[TBL] [Abstract][Full Text] [Related]
14. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
Thomas RE; Armstrong DT; Gilchrist RB
Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932
[TBL] [Abstract][Full Text] [Related]
16. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
[TBL] [Abstract][Full Text] [Related]
18. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
Zhu WH; Majluf-Cruz A; Omburo GA
Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterases in the rat renal vasculature.
Jackson EK; Mi Z; Carcillo JA; Gillespie DG; Dubey RK
J Cardiovasc Pharmacol; 1997 Dec; 30(6):798-801. PubMed ID: 9436820
[TBL] [Abstract][Full Text] [Related]
20. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase.
Wright CD; Kuipers PJ; Kobylarz-Singer D; Devall LJ; Klinkefus BA; Weishaar RE
Biochem Pharmacol; 1990 Aug; 40(4):699-707. PubMed ID: 1696820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
